Advertisement
Screener

LIFEVANTAGE CORP (LFVN) Debt / Equity

Lifevantage Corp Debt/Equity Ratio

The debt/equity ratio shows how much a company has borrowed for every dollar its shareholders have put in. It is long-term debt, both the part due within a year and the rest, divided by shareholder equity, shown as a multiple with both amounts in the table. A higher ratio means the company relies more on borrowed money than on shareholder capital. Because equity shrinks through buybacks or losses, the ratio can rise even when debt is unchanged, and it has no meaning when equity is negative. Quarterly points use quarter-end balances; annual points use fiscal-year-end balances.

  • Lifevantage Corp debt/equity ratio for the quarter ending 2019-06-30 was 0.05, a 78.32% decline year-over-year.
  • Lifevantage Corp debt/equity ratio for the quarter ending 2019-03-31 was 0.08, a 74.64% decline year-over-year.
  • Lifevantage Corp debt/equity ratio for the quarter ending 2018-12-31 was 0.21, a 46.16% decline year-over-year.
  • Lifevantage Corp debt/equity ratio for the quarter ending 2018-09-30 was 0.21, a 52.53% decline year-over-year.
  • Lifevantage Corp debt/equity ratio for fiscal 2019 was 0.05, a 78.32% decline from fiscal 2018.
  • Lifevantage Corp debt/equity ratio for fiscal 2018 was 0.25, a 51.85% decline from fiscal 2017.
  • Lifevantage Corp debt/equity ratio for fiscal 2017 was 0.51, a 42.04% decline from fiscal 2016.
  • Lifevantage Corp debt/equity ratio for fiscal 2016 was 0.88, a 91.89% decline from fiscal 2015.
Available history
2013-06-30 to 2019-06-30
Data captured

Historical Debt/Equity Ratio

DateDebt/Equity RatioLong-term debtShareholder equity
2019-06-300.05$1.45M$27.2M
2019-03-310.08$1.94M$24.75M
2018-12-310.21$4.43M$21.02M
2018-09-300.21$4.92M$23.53M
2018-06-300.25$5.41M$21.95M
2018-03-310.31$5.97M$19.3M
2017-12-310.39$6.46M$16.51M
2017-09-300.44$6.95M$15.77M
2017-06-300.51$7.44M$14.53M
2017-03-310.57$7.93M$13.9M
2016-12-310.58$8.42M$14.51M
2016-09-300.63$8.92M$14.08M
2016-06-300.88$9.41M$10.65M
2016-03-311.12$9.9M$8.84M
2015-12-311.89$13.27M$7.01M
2015-09-303.66$16.74M$4.58M
2015-06-3010.89$19.67M$1.81M
2015-03-319.33$26.4M$2.83M
2014-12-316.05$27.52M$4.55M
2014-09-303.98$28.65M$7.2M
2014-06-3012.76$29.77M$2.33M
2014-03-3116.4$44.73M$2.73M
2013-12-31-83.68$45.86M-$548,000.00
2013-06-300$0.00$33.95M

Annual Debt/Equity Ratio

DateDebt/Equity RatioLong-term debtShareholder equity
2019-06-300.05$1.45M$27.2M
2018-06-300.25$5.41M$21.95M
2017-06-300.51$7.44M$14.53M
2016-06-300.88$9.41M$10.65M
2015-06-3010.89$19.67M$1.81M
2014-06-3012.76$29.77M$2.33M
2013-06-300$0.00$33.95M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Adicet Bio, Inc. (ACET)United States$0.078B-0.81
Valion Bio, Inc. (VBIO)United States$0.077B
MAIA Biotechnology, Inc. (MAIA)United States$0.077B-2.30
iBio, Inc. (IBIO)United States$0.077B-2.94
Verrica Pharmaceuticals Inc. (VRCA)United States$0.076B-3.39
OS Therapies Inc (OSTX)United States$0.076B-2.17
Gain Therapeutics, Inc. (GANX)United States$0.080B-4.40
Aldeyra Therapeutics, Inc. (ALDX)United States$0.074B-5.57
Cingulate Inc. (CING)United States$0.073B-2.64
Spero Therapeutics, Inc. (SPRO)United States$0.073B17.41